Status:
COMPLETED
A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This single arm study assessed the efficacy and safety of subcutaneous methoxy polyethylene glycol-epoetin beta (Mircera), a continuous erythropoietin receptor activator (C.E.R.A.), for correction and...
Eligibility Criteria
Inclusion
- Adult participants, \>=18 years of age;
- Chronic renal anemia;
- No ESA therapy during previous 3 months.
Exclusion
- Transfusion of red blood cells during previous 2 months;
- Poorly controlled hypertension requiring hospitalization in previous 6 months;
- Significant acute or chronic bleeding.
Key Trial Info
Start Date :
June 30 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2009
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00642668
Start Date
June 30 2008
End Date
December 31 2009
Last Update
July 5 2017
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
ASZ Aalst
Aalst, Belgium, 9300
2
ZNA Middelheim
Antwerp, Belgium, 2020
3
ZNA Stuivenberg
Antwerp, Belgium, 2060
4
AZ Sint Lucas Brugge
Assebroek, Belgium, 8310